These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35941663)

  • 1. Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma.
    Zhao J; Liang J; Yang Y; Sun G; Zhang X; Zhao J; Hu X; Chen J; Zhu S; Ni Y; Zhang Y; Dai J; Wang Z; Wang Z; Zeng Y; Yao J; Chen N; Shen P; Liu Z; Zeng H
    Clin Epigenetics; 2022 Aug; 14(1):99. PubMed ID: 35941663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
    Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
    Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma.
    Zhao J; Pan X; Wang Z; Chen Y; Liu D; Shen Y; Wei X; Xu C; Zhang X; Hu X; Chen J; Zhao J; Tang B; Sun G; Shen P; Liu Z; Zeng H; Liang J
    Eur J Med Res; 2024 Jul; 29(1):378. PubMed ID: 39033192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Expression and Prognostic Implications of Krüppel-Like Factor 3 (KLF3) in Clear Cell Renal Cell Carcinoma.
    Wan B; Zhang W; Deng X; Lu Y; Zhang Z; Yang Y
    Crit Rev Eukaryot Gene Expr; 2024; 34(2):45-59. PubMed ID: 38073441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
    Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
    J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic modification of Castor zinc finger 1 (CASZ1) is associated with tumor microenvironments and prognosis of clear cell renal cell carcinoma.
    Li F; Liang J; Wei X
    Int J Surg; 2024 Sep; ():. PubMed ID: 39235847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of Tumor Microenvironment-Associated Signature in Clear-Cell Renal Cell Carcinoma through Integration of DNA Methylation and Gene Expression.
    Ye Z; Xu J; Zhang X; Zhang Y; Ivanova D; Lu W; Zhang J; Li F; Chen X; Wang Y; Wang M; Xie B
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
    Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
    Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma.
    Huang G; Zhan X; Shen L; Lou L; Dai Y; Jiang A; Gao Y; Wang Y; Xie X; Zhang J
    Clin Exp Med; 2024 Sep; 24(1):212. PubMed ID: 39249558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
    Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
    Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
    Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
    Front Immunol; 2022; 13():935595. PubMed ID: 35935986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma.
    Chang A; Chakiryan NH; Du D; Stewart PA; Zhang Y; Tian Y; Soupir AC; Bowers K; Fang B; Morganti A; Teer JK; Kim Y; Spiess PE; Chahoud J; Noble JD; Putney RM; Berglund AE; Robinson TJ; Koomen JM; Wang L; Manley BJ
    Eur Urol; 2022 Oct; 82(4):354-362. PubMed ID: 35718636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLC22A8: An indicator for tumor immune microenvironment and prognosis of ccRCC from a comprehensive analysis of bioinformatics.
    Xu K; Wu Y; Chi H; Li Y; She Y; Yin X; Liu X; He B; Li X; Du H
    Medicine (Baltimore); 2022 Sep; 101(37):e30270. PubMed ID: 36123895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.